Evoke Pharma Inc. (EVOK) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Evoke Pharma Inc. (EVOK)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.26

0.03 (0.71%)

At close: Jan 14, 2025, 3:58 PM

4.31

1.17%

After-hours Jan 14, 2025, 03:59 PM EST

undefined% (undefined)

Bid	4.08
Market Cap	6.33M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-10.13
PE Ratio (ttm)	-0.42
Forward PE	n/a
Analyst	n/a

Ask	4.51
Volume	12,174
Avg. Volume (20D)	401,962
Open	4.17
Previous Close	4.23
Day's Range	4.17 - 4.49
52-Week Range	3.54 - 12.32
Beta	undefined

About EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine ...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Sep 25, 2013

Employees 4

Stock Exchange NASDAQ

Ticker Symbol EVOK

Website https://www.evokepharma.com

Next Earnings Release

Evoke Pharma Inc. is scheduled to release its earnings on Mar 13, 2025, during market hours.
Analysts project revenue of $3.74M, reflecting a 123.15% YoY growth and earnings per share of -0.25, making a -96.47% decrease YoY.

Why Price Moved

3 weeks ago · Source

+24.77%

Evoke Pharma shares are trading higher after the c... Unlock content with Pro Subscription

2 months ago · Source

+33.58%

Evoke Pharma shares are trading higher after the company announced the presentation of GLP-1 data for users with diabetic gastoparesis using GIMOTI and showed statistically significant improvements.

News

2 months ago · proactiveinvestors.co.uk

Ladbrokes and William Hill owners Entain and Evoke jump on Budget relief

Shares in bookmakers galloped higher after the UK Budget, led by Ladbrokes and Coral owner Entain PLC (LSE:ENT), which rose over 8%, and William Hill owner Evoke PLC, rising 12%. Paddy Power and Betfa...

2 months ago · proactiveinvestors.co.uk

Evoke reports first quarter of growth in over two years

William Hill and 888 owner Evoke PLC (LSE:EVOK) has reported a 3% increase in revenue to £417 million for the third quarter of 2024, compared to the same period last year. It highlighted that this mar...